The valuation of private companies held by Neil Woodford is under more scrutiny with one of the embattled fund manager’s largest holdings set to raise cash far below its valuation.
Benevolent AI, a company that uses artificial intelligence to try to discover new drugs and has a joint venture with Astrazeneca, the pharmaceuticals group, has been a big investment for Mr Woodford, making up 4.5 per cent of his Equity Income fund and 8.4 per cent of his listed Patient Capital Trust.
